[go: up one dir, main page]

WO2007146163A3 - Fc-fusion proteins with reduced fc-mediated effector activities - Google Patents

Fc-fusion proteins with reduced fc-mediated effector activities Download PDF

Info

Publication number
WO2007146163A3
WO2007146163A3 PCT/US2007/013567 US2007013567W WO2007146163A3 WO 2007146163 A3 WO2007146163 A3 WO 2007146163A3 US 2007013567 W US2007013567 W US 2007013567W WO 2007146163 A3 WO2007146163 A3 WO 2007146163A3
Authority
WO
WIPO (PCT)
Prior art keywords
mediated effector
reduced
fusion proteins
effector activities
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/013567
Other languages
French (fr)
Other versions
WO2007146163A2 (en
Inventor
Le Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WELSON PHARMACEUTICALS Inc
Original Assignee
WELSON PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WELSON PHARMACEUTICALS Inc filed Critical WELSON PHARMACEUTICALS Inc
Publication of WO2007146163A2 publication Critical patent/WO2007146163A2/en
Publication of WO2007146163A3 publication Critical patent/WO2007146163A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides Fc fusion proteins with reduced or no Fc-mediated effector activities for use in therapy. Fc fusions proteins produced in accordance with the present invention are easy to purify, have longer circulating half lives compared to proteins without the Fc portion, and yet have minimal or no Fc-mediated effector activities.
PCT/US2007/013567 2006-06-09 2007-06-08 Fc-fusion proteins with reduced fc-mediated effector activities Ceased WO2007146163A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81252806P 2006-06-09 2006-06-09
US60/812,528 2006-06-09

Publications (2)

Publication Number Publication Date
WO2007146163A2 WO2007146163A2 (en) 2007-12-21
WO2007146163A3 true WO2007146163A3 (en) 2008-04-03

Family

ID=38832420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013567 Ceased WO2007146163A2 (en) 2006-06-09 2007-06-08 Fc-fusion proteins with reduced fc-mediated effector activities

Country Status (1)

Country Link
WO (1) WO2007146163A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109879969B (en) * 2017-12-06 2024-04-09 天士力生物医药股份有限公司 A HM-3 fusion protein and its application
CN118852460A (en) * 2017-12-28 2024-10-29 尤利乌斯·马克西米利安维尔茨堡大学 Tumor necrosis factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion protein with FcγR-independent agonist activity (TNFRSF receptor-activating antibody fusion protein with FcγR-independent agonist activity; TRAAFFIAA)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007809A2 (en) * 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
US20060083747A1 (en) * 2002-12-27 2006-04-20 Domantis Limited Fc fusion
WO2006059110A2 (en) * 2004-12-02 2006-06-08 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060083747A1 (en) * 2002-12-27 2006-04-20 Domantis Limited Fc fusion
WO2005007809A2 (en) * 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
WO2006059110A2 (en) * 2004-12-02 2006-06-08 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies

Also Published As

Publication number Publication date
WO2007146163A2 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
AU2013362789A8 (en) Treatment of CD47+ disease cells with SIRP Alpha-Fc fusions
WO2008157378A3 (en) Rage fusion proteins
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2007060117A3 (en) Chimeric keratin-binding effector proteins
WO2004099249A3 (en) Optimized fc variants and methods for their generation
EP2024507A4 (en) Fusion proteins, uses thereof and processes for producing same
NL2000626A1 (en) Rage fusion proteins, preparations and methods for their use.
WO2008030558A3 (en) Modified human plasma polypeptide or fc scaffolds and their uses
WO2010065954A3 (en) Sparc binding peptides and uses thereof
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
EP1912667A4 (en) Concentrated protein lyophilates, methods, and uses
EP2937361A3 (en) Fc variants with altered binding to fcRn
WO2006127757A3 (en) Interferon-igg fusion
WO2007041635A3 (en) Fc variants with optimized fc receptor binding properties
WO2004029207A3 (en) Optimized fc variants and methods for their generation
WO2007007173A3 (en) Human anti-madcam antibodies
WO2008104803A3 (en) Proteins
WO2006133089A3 (en) Improved human interferon molecules and their uses
BRPI0511396A (en) Retinal Derivatives and Methods for Use in the Treatment of Visual Disorders
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
WO2010014922A3 (en) Protein purification tags and uses thereof
DE102005020647A8 (en) Connector, connector system and use
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07795924

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07795924

Country of ref document: EP

Kind code of ref document: A2